PL436491A1 - Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19 - Google Patents

Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19

Info

Publication number
PL436491A1
PL436491A1 PL436491A PL43649120A PL436491A1 PL 436491 A1 PL436491 A1 PL 436491A1 PL 436491 A PL436491 A PL 436491A PL 43649120 A PL43649120 A PL 43649120A PL 436491 A1 PL436491 A1 PL 436491A1
Authority
PL
Poland
Prior art keywords
treatment
cov
sars
virus
covid
Prior art date
Application number
PL436491A
Other languages
English (en)
Other versions
PL244438B1 (pl
Inventor
Norbert Odolczyk
Piotr Zielenkiewicz
Maria WINIEWSKA-SZAJEWSKA
Jarosław Poznański
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL436491A priority Critical patent/PL244438B1/pl
Priority to US18/270,019 priority patent/US20240082341A1/en
Priority to PCT/PL2021/050094 priority patent/WO2022146154A2/en
Priority to EP21863044.0A priority patent/EP4267248A2/en
Publication of PL436491A1 publication Critical patent/PL436491A1/pl
Publication of PL244438B1 publication Critical patent/PL244438B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia są ulepszone peptydy nadające się do blokowania interakcji pomiędzy glikoproteiną S wirusa SARS-CoV-2, a ludzkim receptorem ACE2, zwłaszcza w celu leczenia, bądź wspomagania leczenia infekcji wywołanej wirusem SARS-COV-2 i/lub wirusami wykazującymi wysokie podobieństwo sekwencyjnie genomu do wirusa SARS-CoV-2.
PL436491A 2020-12-28 2020-12-28 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19 PL244438B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL436491A PL244438B1 (pl) 2020-12-28 2020-12-28 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19
US18/270,019 US20240082341A1 (en) 2020-12-28 2021-12-28 Peptide for use in the treatment or prevention of covid-19
PCT/PL2021/050094 WO2022146154A2 (en) 2020-12-28 2021-12-28 Peptide for use in the treatment or prevention of covid-19
EP21863044.0A EP4267248A2 (en) 2020-12-28 2021-12-28 Peptide for use in the treatment or prevention of covid-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL436491A PL244438B1 (pl) 2020-12-28 2020-12-28 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19

Publications (2)

Publication Number Publication Date
PL436491A1 true PL436491A1 (pl) 2022-07-04
PL244438B1 PL244438B1 (pl) 2024-01-29

Family

ID=80448660

Family Applications (1)

Application Number Title Priority Date Filing Date
PL436491A PL244438B1 (pl) 2020-12-28 2020-12-28 Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19

Country Status (4)

Country Link
US (1) US20240082341A1 (pl)
EP (1) EP4267248A2 (pl)
PL (1) PL244438B1 (pl)
WO (1) WO2022146154A2 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2007060546A2 (en) * 2005-05-31 2007-05-31 Bengt Guss Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
CA3064714A1 (en) * 2017-05-23 2018-11-29 Dragonfly Therapeutics, Inc. A protein binding nkg2d, cd16 and a tumor-associated antigen
AU2019212486A1 (en) * 2018-01-24 2019-08-29 Trait Biosciences, Inc. Systems and methods for enhancing trichome formation and density in

Also Published As

Publication number Publication date
WO2022146154A3 (en) 2022-08-04
EP4267248A2 (en) 2023-11-01
PL244438B1 (pl) 2024-01-29
WO2022146154A2 (en) 2022-07-07
US20240082341A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
CL2020003384A1 (es) Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a
MX392533B (es) Anticuerpos humanos contra glicoproteina del virus ebola.
JOP20220349A1 (ar) توليفة لقاح ضد الإصابة بفيروس مخلوي تنفسي
MX2020001402A (es) Metodos de terapia genica del factor viii (fviii).
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
MX2022015071A (es) Moleculas de anticuerpo contra el virus bk.
EA202193119A1 (ru) Профилактическое лечение инфекции, вызванной респираторно-синцитиальным вирусом, вакциной на основе аденовируса
PE20081215A1 (es) Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados
PH12022552086A1 (en) Vaccine against african swine fever virus infection
WO2020014591A8 (en) Apmv and uses thereof for the treatment of cancer
RU2012120671A (ru) Рекомбинантный человеческий белок сс10 для лечения гриппа
WO2022013696A9 (en) Recombinant vaccinia virus
PL436491A1 (pl) Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
PL435261A1 (pl) Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
PH12020551944A1 (en) Reverse peptide vaccine
BR112022015502A2 (pt) Tratamento da infecção por coronavírus com interferon lambda
PH12021551332A1 (en) Use of cocculus hirsutus extract for treating dengue
CA3242034A1 (en) Pharmaceutical composition for treatment of viral infections
EA200501569A1 (ru) Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина
EA202092732A1 (ru) АНТИТЕЛА, КОТОРЫЕ НАЦЕЛЕНЫ НА ГЛИКОПРОТЕИН gp120 ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX2022012487A (es) Métodos para tratar y/o prevenir infecciones y/o enfermedades virales causadas por virus en un sujeto que lo necesita.
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero